Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04149899 · ClinicalTrials.gov registry record · Phase 1
Safety and IOP-Lowering Effects of WB007
A Phase 1 study of Ocular Hypertension and Glaucoma, Primary Open Angle, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT04149899 is a Phase 1 study of Ocular Hypertension and Glaucoma, Primary Open Angle that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 77 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04149899, a Phase 1 study of Ocular Hypertension and Glaucoma, Primary Open Angle, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one eye. Part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of WB007 (selected based on Part 1 results) in both eyes compared with timolol 0.5% for 14 days.
Conditions Studied
Interventions
- DRUG WB007 0.05%
- DRUG WB007 0.15%
- DRUG WB007 0.4%
- DRUG Timolol 0.5%
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04149899
The ClinicalTrials.gov registry entry for NCT04149899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (72% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which WB007 0.05% is the first listed.
NCT04149899 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04149899 about?
NCT04149899 is a clinical study titled "Safety and IOP-Lowering Effects of WB007". The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one ...
What is the current status of trial NCT04149899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2019-11-14. Estimated completion is 2022-12-14.
What conditions does trial NCT04149899 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT04149899?
The interventions under investigation include: WB007 0.05% (DRUG), WB007 0.15% (DRUG), WB007 0.4% (DRUG), Timolol 0.5% (DRUG).
Who is sponsoring clinical trial NCT04149899?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04149899 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.